If your gastroenterologist has prescribed Omvoh for Crohn's disease and you have Aetna, you are asking a reasonable question with very little public guidance behind it. Omvoh, the brand name for mirikizumab, only earned its Crohn's indication in 2025, which makes it one of the newest biologics in the inflammatory bowel disease toolkit. Aetna does list it in a published coverage policy, so coverage is possible, but it is not automatic. Like most insurers, Aetna treats a brand-new biologic as a later-line agent and gates it behind prior authorization and step therapy. This article maps how Aetna evaluates an Omvoh request for Crohn's, what its policy typically requires, and what to do if the first answer is no. Always confirm the specifics against your own plan documents, because criteria and formularies vary by plan.
What Omvoh Is and When It Is Used
Omvoh is an interleukin-23 antagonist that selectively binds the p19 subunit of IL-23 and blocks its signaling, which is part of the inflammatory pathway in Crohn's disease, according to the FDA prescribing information on DailyMed. The FDA approved Omvoh for moderately to severely active Crohn's disease in adults on January 15, 2025, expanding it beyond its earlier ulcerative colitis indication. The approval rested on the VIVID-1 trial published in The Lancet, in which 45.4% of mirikizumab patients reached CDAI clinical remission versus 19.6% on placebo. Because it arrived so recently, Omvoh is usually positioned after older, more established biologics rather than as a first choice.
How Aetna Handles Pharmacy and Specialty Drugs
Understanding who administers your benefit helps you anticipate the process. Aetna is part of CVS Health, and its pharmacy benefits are administered by CVS Caremark, with CVS Specialty handling specialty medications. Omvoh is a specialty biologic that begins with intravenous induction and shifts to subcutaneous maintenance, so it typically routes through this specialty channel. Practically, that means your prescription, prior authorization, and dispensing often run through CVS Caremark and CVS Specialty rather than a retail pharmacy counter. Whether Omvoh is billed under your pharmacy benefit or your medical benefit can depend on your plan and on where the infusion is given, which affects which prior authorization pathway applies. Confirming this early prevents your request from stalling between two benefit silos.
What Aetna's Clinical Policy Bulletin Typically Requires
Aetna publishes its coverage rules in Clinical Policy Bulletins, and there is a dedicated Clinical Policy Bulletin for mirikizumab, Omvoh. For Crohn's disease, that bulletin generally treats Omvoh as medically necessary only after a member has had a contraindication, intolerance, or inadequate response to preferred targeted immune modulators. The bulletin lists specific agents a member is typically expected to try first.
Entyvio, Skyrizi, Stelara, or Tremfya
The policy also expects the prescription to come from or be made in consultation with a gastroenterologist, and it documents how continued coverage is judged by improvement in symptoms such as abdominal pain, diarrhea, or endoscopic findings. These criteria can change, so read the current bulletin and your own plan before assuming any single requirement applies to you.
The Step Therapy Gate and the Medical Necessity Case
Because Omvoh is so new, the step therapy requirement is the most common obstacle for Crohn's patients. Aetna's bulletin frames Omvoh as appropriate after documented failure of preferred agents, which means a strong request hinges on a clear record of what came before. The most persuasive medical necessity case shows the specific biologics you tried, the dose and duration of each, and exactly how each one failed, whether through loss of response, true intolerance, or a documented contraindication. Objective markers such as endoscopy results, fecal calprotectin, or CDAI scores strengthen the file far more than a general statement that prior treatment did not work. Keeping this history organized before the prior authorization is submitted reduces back-and-forth and gives your gastroenterologist the evidence needed to justify a later-line agent.
What to Do If Aetna Denies Coverage
A denial is not the end of the process. Under federal rules, you have the right to an internal appeal and, if that fails, an independent external review, and you generally have at least a set window after the denial to file. Start by reading the denial letter for the exact reason, because a step therapy denial is addressed differently from a paperwork gap. If the issue is unmet step therapy, your gastroenterologist can submit the documented history of failed preferred agents and request an exception based on medical necessity. If you already failed those agents, supplying the dates, doses, and objective evidence often resolves the denial on internal appeal. Throughout, lean on the specific language in Aetna's mirikizumab bulletin and your plan documents, and request an expedited review if a delay would harm your health.
Conclusion
Aetna can cover Omvoh for Crohn's disease, but coverage is conditional rather than guaranteed, and the path runs through prior authorization, the CVS Caremark and CVS Specialty channel, and a step therapy requirement that reflects how recently the drug was approved. The members who succeed are usually the ones who treat the prior authorization as a documentation exercise, assembling a clear record of which preferred biologics were tried and how each one failed. Because formularies, tiers, and bulletin criteria shift over time and differ across plans, the single most reliable step is to read your current plan documents and the active Clinical Policy Bulletin, then build the medical necessity file with your gastroenterologist before the request is ever submitted.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.